- Home
- ATNI vs HQL Comparison
ATNI vs HQL Comparison
Compare ATNI & HQL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ATNI | HQL |
|---|---|---|
| Founded | 1987 | 1992 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Investment Managers |
| Sector | Telecommunications | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 392.6M | 490.5M |
| IPO Year | 1994 | N/A |
Fundamental Metrics
Financial Performance| Metric | ATNI | HQL |
|---|---|---|
| Price | $25.59 | $16.81 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 72.6K | ★ 104.6K |
| Earning Date | 04-29-2026 | 01-01-0001 |
| Dividend Yield | 4.04% | ★ 11.56% |
| EPS Growth | ★ 34.29 | N/A |
| EPS | N/A | ★ 0.79 |
| Revenue | ★ $727,975,000.00 | N/A |
| Revenue This Year | $3.12 | N/A |
| Revenue Next Year | $1.10 | N/A |
| P/E Ratio | ★ N/A | $21.52 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $13.76 | $10.55 |
| 52 Week High | $30.45 | $17.80 |
Technical Indicators
Market Signals| Indicator | ATNI | HQL |
|---|---|---|
| Relative Strength Index (RSI) | 42.45 | 55.34 |
| Support Level | $22.44 | $16.40 |
| Resistance Level | $26.80 | $17.40 |
| Average True Range (ATR) | 0.97 | 0.35 |
| MACD | -0.08 | 0.09 |
| Stochastic Oscillator | 14.74 | 83.75 |
Price Performance
Historical ComparisonAbout ATNI ATN International Inc.
ATN International Inc is a telecommunications and utilities company. The company provides digital infrastructure and communications services with a focus on rural and remote markets in the United States, and internationally, including Bermuda and the Caribbean region. Its operating segments comprise U.S. Telecom and International Telecom. The company earns revenue from its International telecommunication segment.
About HQL abrdn Life Sciences Investors Shares of Beneficial Interest
abrdn Life Sciences Investors operates as a non-diversified closed-end management investment company. Its investment objective is to seek long-term capital appreciation by investing mainly in securities of life sciences companies. It invests in securities of public and private companies that are believed by the Fund's Investment Adviser to have the potential for above-average growth.